Drug intelligence / Profile preview

NOBO-205

Development stage: Unknown
Lead developer: NOBO Medicine
Modality: Small Molecules
Administration: Oral

Overview

**NOBO-205** is a NOBO Medicine investigational, poseltinib-based combination-development program for relapsed or refractory secondary central nervous system lymphoma. Poseltinib is a central nervous system-penetrant small-molecule inhibitor of Bruton's tyrosine kinase and tyrosine-protein kinase TEC, intended to suppress B-cell receptor signaling and potential TEC-mediated bypass signaling in malignant B cells. The exact fixed component regimen for NOBO-205 is not publicly delineated in the available pipeline information; NOBO Medicine has separately described poseltinib combination strategies involving agents including lenalidomide, rituximab, glofitamab, and golcadomide.

Targets

TEC (TEC proto-oncogene tyrosine-protein kinase)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on NOBO-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOBO-205.

Explore the full profile